Nice faces court action over drug decision

A recommendation by the body responsible for providing guidance on NHS drugs is to be challenged in court for the first time.

Two drugs companies, Eisai and Pfizer, are applying to the High Court for a judicial review into a decision made by the National Institute for Health and Clinical Excellence (Nice) regarding medication for Alzheimer's disease.

Nice recently recommended that certain treatments, including donepezil, rivastigmine and galantamine, should not be made available for sufferers of mild, recently-diagnosed Alzheimer's disease on the NHS.

The drugs could improve the lives of sufferers for as little as £2.50 a day, campaigners say, but patients will now be forced to seek private treatment or receive alternative medication on the NHS.

"We are deeply concerned about the way that Nice's decision on treatment recommendations for early Alzheimer's disease was reached," said Paul Hooper, the managing director of Eisai.

"These flawed conclusions will have a devastating impact on the lives of thousands of people affected by this terrible disease."

Nice has confirmed that it will act appropriately in any court proceedings that may take place.

Comment on this page »


Latest news

Chelsea and Westminster named the best place to work in the NHS for 2015

Nuffield Health opens doors of new Cambridge Hospital

Nuffield Health plans to open state-of-the-art diagnostic suite

Nice faces court action over drug decision
Connect with us on:

This site compiles with the HONcode standard for trustworthy health information